Circular Rna Based Therapeutics Market

According to Stratistics MRC, the Global Circular RNA-Based Therapeutics Market is accounted for $0.3 billion in 2026 and is expected to reach $2.5 billion by 2034 growing at a CAGR of 30.3% during the forecast period. The Circular RNA-Based Therapeutics Market encompasses emerging therapeutic platforms utilizing engineered circular RNA molecules to enable sustained protein expression, immune modulation, and targeted cellular engineering. Increasing investment in RNA medicine, growing demand for innovative treatments, and advancements in nucleic acid delivery technologies are supporting market development. Innovations in RNA circularization, translation enhancement, and lipid nanoparticle formulations improve therapeutic potential. Expanding biotechnology partnerships and clinical research initiatives create additional growth opportunities.

Market Dynamics:

Driver:

Increasing investment in RNA therapeutics and demand for sustained protein expression

Increasing investment in RNA therapeutics and demand for sustained protein expression is driving market growth. Circular RNA molecules possess covalently closed structures that can provide greater resistance to exonuclease degradation than conventional linear RNA. This characteristic offers potential advantages for prolonged therapeutic protein production and reduced dosing frequency. Advancements in RNA circularization, internal ribosome entry sites, and translation optimization improve platform capabilities. Growing pharmaceutical investment in programmable medicines and next-generation nucleic acid therapeutics further supports research and development activities.

Restraint:

Complex manufacturing processes and limited clinical validation of circular RNA therapies

Complex manufacturing processes and limited clinical validation of circular RNA therapies restrain market growth. Producing high-purity circular RNA requires specialized circularization methods, removal of linear RNA impurities, and stringent quality control procedures. Therapeutic performance depends on RNA stability, translation efficiency, tissue delivery, and appropriate immune responses. Limited human clinical evidence creates uncertainty regarding long-term safety and effectiveness. High development costs, manufacturing scalability challenges, and evolving regulatory expectations further complicate commercialization of emerging circular RNA therapeutic platforms.

Opportunity:

Expansion of circular RNA platforms for in vivo cell engineering and cancer immunotherapy

Expansion of circular RNA platforms for in vivo cell engineering and cancer immunotherapy presents significant growth opportunities. Biotechnology companies are investigating engineered circular RNA molecules capable of expressing therapeutic proteins and reprogramming selected immune cells within the body. Growing research into oncology, autoimmune diseases, and genetic disorders encourages pipeline diversification. Advancements in targeted lipid nanoparticles and RNA translation engineering improve delivery possibilities. Strategic collaborations among pharmaceutical companies, biotechnology developers, and research institutions are expected to accelerate clinical translation.

Threat:

Immunogenicity concerns and competition from established RNA therapeutic technologies

Immunogenicity concerns and competition from established RNA therapeutic technologies pose significant challenges to market development. Circular RNA formulations must demonstrate predictable protein expression, acceptable safety profiles, and controlled biological activity. Unintended immune stimulation, manufacturing impurities, or inefficient tissue targeting may affect clinical outcomes. Established messenger RNA, antisense oligonucleotide, and gene therapy platforms provide competing therapeutic approaches. Intellectual property disputes and regulatory uncertainty surrounding novel RNA modalities may further influence investment decisions, clinical development timelines, and commercialization prospects.

Covid-19 Impact:

The COVID-19 pandemic disrupted biotechnology research through delayed clinical trials, restricted laboratory operations, and interruptions in specialized manufacturing supply chains. However, successful deployment of messenger RNA vaccines accelerated investment in RNA medicine, nucleic acid delivery platforms, and advanced bio manufacturing infrastructure. This momentum encouraged broader exploration of next-generation RNA technologies, including circular RNA therapeutics. Growing familiarity with lipid nanoparticle delivery and RNA manufacturing supported platform development. Post-pandemic expansion of programmable medicine research continues to create opportunities for circular RNA applications.

The protein expression therapeutics segment is expected to be the largest during the forecast period

The protein expression therapeutics segment is expected to account for the largest market share during the forecast period due to growing research into sustained production of therapeutic proteins using engineered circular RNA. These platforms are designed to express selected proteins within target cells while potentially offering improved molecular stability compared with linear RNA. Increasing investigation of enzyme replacement, antibody expression, and regenerative medicine applications supports development. Advancements in circularization efficiency and translation optimization encourage clinical research. Expanding biotechnology investment further strengthens segment prospects.

The lipid nanoparticles (LNPs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the lipid nanoparticles (LNPs) segment is predicted to witness the highest growth rate due to increasing demand for scalable non-viral delivery of circular RNA therapeutics. LNP formulations can protect RNA payloads during administration and facilitate cellular uptake. Growing interest in targeted protein expression and in vivo immune cell engineering encourages delivery platform innovation. Advances in ionizable lipids, tissue targeting, and endosomal escape could expand therapeutic applications. Clinical validation remains essential to establish safety, delivery efficiency, and therapeutic effectiveness.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to extensive biotechnology research infrastructure, substantial venture capital investment, and strong pharmaceutical innovation capabilities. The United States and Canada support circular RNA therapeutic development through specialized biotechnology companies, academic research institutions, and advanced manufacturing networks. Growing investment in cancer immunotherapy, cell engineering, and RNA-based medicine encourages regional market development. Strategic partnerships among pharmaceutical organizations and emerging RNA technology developers further strengthen North America's position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding biotechnology infrastructure, increasing investment in advanced therapeutics, and growing research into nucleic acid medicines. China, Japan, South Korea, India, and Australia are advancing RNA manufacturing capabilities and precision medicine initiatives. Government-supported biotechnology programs and expanding pharmaceutical research activities encourage innovation. Improvements in RNA synthesis, nanoparticle delivery, and clinical development infrastructure are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the Circular RNA-Based Therapeutics Market include Orna Therapeutics, Inc., Sail Biomedicines, Inc., Orbital Therapeutics, Inc., RiboX Therapeutics, Therorna Inc., CirCode Biomed, Circio Holding ASA, Chimerna Therapeutics, Inc., Torque Bio, Inc., Circurna, Circode Therapeutics, Eli Lilly and Company, Merck KGaA, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Twist Bioscience Corporation, Creative Biogene, and Eterna Therapeutics Inc.

Key Developments:

In October 2026, Circio Holding ASA presented new research at the European Society of Gene and Cell Therapy annual meeting, highlighting its circVec 5.2 platform for enhanced cardiac gene expression and tissue specificity. The development demonstrated continued progress in vector-encoded circular RNA technology and its potential applications in cardiovascular gene therapy and in vivo cellular engineering.

In July 2026, Sail Biomedicines, Inc. announced a strategic collaboration with Johnson & Johnson to develop next-generation in vivo CAR-T therapies for immune-mediated diseases. The collaboration focuses on Sail's Endless RNA technology and targeted nanoparticle platform, designed to enable transient therapeutic protein expression and direct immune cell engineering within the body.

In February 2026, Eli Lilly and Company announced an agreement to acquire Orna Therapeutics, Inc., expanding its capabilities in circular RNA-based medicines and in vivo cell engineering. The transaction includes Orna's engineered circular RNA and lipid nanoparticle technologies, along with its ORN-252 program targeting CD19-positive B cells for potential treatment of autoimmune diseases.

Therapeutic Modalities Covered:
• Protein Expression Therapeutics
• In Vivo Cell Engineering Therapeutics
• Therapeutic Vaccines
• Regulatory & Non-Coding circRNA Therapeutics
• Other Therapeutic Modalities

Technologies Covered:
• In Vitro Synthesized circRNA
• Vector-Encoded circRNA
• Engineered Translation-Enhanced circRNA
• Other Technologies

Delivery Methods Covered:
• Lipid Nanoparticles (LNPs)
• Viral Vector-Based Delivery
• Polymer-Based Nanoparticles
• Other Delivery Methods

Routes of Administration Covered:
• Intravenous
• Intramuscular
• Subcutaneous
• Local & Intratissue Administration
• Other Routes of Administration

Applications Covered:
• Oncology
• Autoimmune & Inflammatory Diseases
• Infectious Diseases
• Genetic & Rare Diseases
• Cardiovascular & Metabolic Disorders
• Other Applications

End Users Covered:
• Hospitals & Specialty Clinics
• Cancer & Cell Therapy Centers
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Contract Research Organizations (CROs)
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances